USD
$0.00
(0.00%
)At Close (As of Sep 5, 2025)
$800.74M
Market Cap
-
P/E Ratio
-0.18
EPS
$4.07
52 Week High
$1.24
52 Week Low
HEALTHCARE
Sector
Field | Value (USD) |
---|---|
Gross Profit | $97M |
Total Revenue | $160M |
Cost Of Revenue | $63M |
Costof Goods And Services Sold | $63M |
Operating Income | -$50M |
Selling General And Administrative | $102M |
Research And Development | $38M |
Operating Expenses | $185M |
Investment Income Net | - |
Net Interest Income | -$18M |
Interest Income | - |
Interest Expense | $18M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $38M |
Income Before Tax | -$69M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$69M |
Comprehensive Income Net Of Tax | - |
Ebit | -$51M |
Ebitda | -$14M |
Net Income | -$69M |
Field | Value (USD) |
---|---|
Total Assets | $221M |
Total Current Assets | $114M |
Cash And Cash Equivalents At Carrying Value | $52M |
Cash And Short Term Investments | $52M |
Inventory | $16M |
Current Net Receivables | $34M |
Total Non Current Assets | $107M |
Property Plant Equipment | - |
Accumulated Depreciation Amortization Ppe | - |
Intangible Assets | - |
Intangible Assets Excluding Goodwill | - |
Goodwill | $59M |
Investments | - |
Long Term Investments | - |
Short Term Investments | - |
Other Current Assets | $11M |
Other Non Current Assets | - |
Total Liabilities | $270M |
Total Current Liabilities | $81M |
Current Accounts Payable | $15M |
Deferred Revenue | - |
Current Debt | - |
Short Term Debt | $5.4M |
Total Non Current Liabilities | $189M |
Capital Lease Obligations | $8.9M |
Long Term Debt | $39M |
Current Long Term Debt | - |
Long Term Debt Noncurrent | - |
Short Long Term Debt Total | $48M |
Other Current Liabilities | $45M |
Other Non Current Liabilities | $104M |
Total Shareholder Equity | -$49M |
Treasury Stock | - |
Retained Earnings | -$1.7B |
Common Stock | $2K |
Common Stock Shares Outstanding | $211M |
Field | Value (USD) |
---|---|
Operating Cashflow | -$41M |
Payments For Operating Activities | - |
Proceeds From Operating Activities | - |
Change In Operating Liabilities | - |
Change In Operating Assets | - |
Depreciation Depletion And Amortization | $38M |
Capital Expenditures | $33K |
Change In Receivables | - |
Change In Inventory | -$28M |
Profit Loss | - |
Cashflow From Investment | -$33K |
Cashflow From Financing | $50M |
Proceeds From Repayments Of Short Term Debt | - |
Payments For Repurchase Of Common Stock | - |
Payments For Repurchase Of Equity | - |
Payments For Repurchase Of Preferred Stock | - |
Dividend Payout | - |
Dividend Payout Common Stock | - |
Dividend Payout Preferred Stock | - |
Proceeds From Issuance Of Common Stock | - |
Proceeds From Issuance Of Long Term Debt And Capital Securities Net | - |
Proceeds From Issuance Of Preferred Stock | - |
Proceeds From Repurchase Of Equity | -$1.3M |
Proceeds From Sale Of Treasury Stock | - |
Change In Cash And Cash Equivalents | - |
Change In Exchange Rate | - |
Net Income | -$69M |
Field | Value (USD) |
---|---|
Gross Profit | $97M |
Total Revenue | $160M |
Cost Of Revenue | $63M |
Costof Goods And Services Sold | $63M |
Operating Income | -$50M |
Selling General And Administrative | $102M |
Research And Development | $38M |
Operating Expenses | $185M |
Investment Income Net | - |
Net Interest Income | -$18M |
Interest Income | - |
Interest Expense | $18M |
Non Interest Income | - |
Other Non Operating Income | - |
Depreciation | - |
Depreciation And Amortization | $38M |
Income Before Tax | -$69M |
Income Tax Expense | - |
Interest And Debt Expense | - |
Net Income From Continuing Operations | -$69M |
Comprehensive Income Net Of Tax | - |
Ebit | -$51M |
Ebitda | -$14M |
Net Income | -$69M |
Sector: HEALTHCARE
Industry: DRUG MANUFACTURERS - SPECIALTY & GENERIC
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of kidney therapies for patients with kidney disease. The company is headquartered in Cambridge, Massachusetts.